Technical Perspectives: Antibody Drug Conjugates

A podcast moderated by Patricia Van Arnum, executive editor of Pharmaceutical Technology.

Antibody drug conjugates represent a niche area of drug development. Antibody drug conjugates combine a small-molecule, often a cytotoxic compound, to a monoclonal antibody. Grant E. Boldt, PhD, director of European business development for SAFC, discusses manufacturing considerations in producing antibody drug conjugates with Patricia Van Arnum, executive editor of Pharmaceutical Technology. Listen to the podcast.

Articles in this issue

almost 15 years ago

Article

World Health Organization Issues Progress Report on Combating HIV/AIDS

almost 15 years ago

Article

CSR and Sustainability in the News

almost 15 years ago

Article

Pharmaceutical Companies Target Green Manufacturing

almost 15 years ago

Article

Patent Reform and the Pharmaceutical Industry: From First-To-File To Post-Grant Review And Beyond

almost 15 years ago

Article

Biosimilars' Technology Needs

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Technical Perspectives: Antibody Drug Conjugates

Articles in this issue

Trending on Pharmaceutical Technology

Mature Medicines Divestment Signals Shift in Manufacturing Strategy

Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response

FDA's IND Pilot Puts CMC Review First

Successful Internal Audit Planning and Execution

CPHI Milan 2026: AI and Bioavailability, Part 1